Skip to main content
OpenTrials
Completed

NCT Number: NCT01042210

Agouti-related Peptide (AgRP) in Healthy Mothers and Mothers With Preeclampsia and Their Offspring

The study is focused on the investigation of possible associations between plasma/serum levels of agouti related peptide (AgRP) and its genetic background in healthy women with physiological pregnancy (non-preeclamptic) and women with preeclampsia, in the postpartum period, and in their offspring.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Preeclampsia Birth Weight Body Weight Female Urogenital Diseases and Pregnancy Complications Hypertension, Pregnancy-Induced Pathological Conditions, Signs and Symptoms Pre-Eclampsia Pregnancy Complications Signs and Symptoms Urogenital Diseases

Age range

18 year–35 year

Sex eligibility

Female

Study type

Observational

Primary location

Masaryk university affiliated hospital, Clinic of Obstetrics and Gynecology

Brno, Moravia, 625 00, Czechia

About this study

The study is focused on investigation of possible genotype-phenotype interactions of agouti-related peptide (AgRP) in postpartum non-preeclamptic women and preeclamptic women and in their offspring.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • For preeclampsia:
  • development of hypertension after the 20th week of pregnancy (systolic blood pressure, ≥140 mmHg; and/or diastolic blood pressure, ≥90 mmHg; measured at rest on two consecutive occasions at least 24 h apart) in previously normotensive women, and the onset of proteinuria (>300 mg of urinary protein/L over 24 h)
  • single-fetus pregnancy
  • age range 18-35 y
  • no preconceptional history of hypertension
  • For mother with physiological pregnancies:
  • uncomplicated
  • spontaneous conception
  • single-fetus pregnancy
  • age range 18-35 y
  • spontaneous uncomplicated delivery
  • no history of preconceptional hypertension

Exclusion criteria

  • For preeclampsia:
  • multiple pregnancy
  • preeclampsia superimposed to chronic hypertension preceding pregnancy
  • kidney disease
  • fetal malformations
  • For mothers with physiological pregnancies:
  • in vitro fertilization
  • fetal malformations
  • multiple pregnancy
  • events of bleeding

Treatment and study plan

Primary outcomes

  1. plasma/serum level of agouti/related peptide in peripheral blood in postpartum mother

    Time frame: 2-4 hours postpartum

  2. Plasma level of agouti-related peptide in umbilical cord blood from the newborn

    Time frame: immediately postpartum

Secondary outcomes

  1. maternal weight gain during pregnancy

    Time frame: using postpartum and peripartum data

  2. birth weight of the newborn

    Time frame: immediately postpartum

  3. maternal preconceptional BMI

    Time frame: anamnestic information

Sponsors and collaborators

Lead sponsor

Masaryk University

Other

Registry information

Official study title

Genotype-phenotype Associations of Agouti-related Peptide (AgRP) in Postpartum Period in Preeclamptic and Non-preeclamptic Women and Their Offspring

Important dates

Study start
2005
Primary completion
2006
Study completion
2006
First posted
Jan 5, 2010
Registry last updated
Jan 5, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.